Analyst Ratings For Bristol-Myers Squibb Co (NYSE:BMY)
Today, BMO Capital Markets lowered its price target on Bristol-Myers Squibb Co (NYSE:BMY) to $56.00 per share.
There are 12 Hold Ratings, 6 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Bristol-Myers Squibb Co (NYSE:BMY) is Hold with a consensus target price of $61.2769 per share, a potential 22.24% upside.
Some recent analyst ratings include
- 11/27/2018-Bristol-Myers Squibb Co (NYSE:BMY) had its Outperform rating reiterated by William Blair
- 10/23/2018-Bristol-Myers Squibb Co (NYSE:BMY) has coverage initiated with a Outperform rating and $66.00 price target
- 10/22/2018-Bristol-Myers Squibb Co (NYSE:BMY) gets downgraded to Neutral by Citigroup with a price target of $57.00
- On 4/30/2018 Dinesh C Paliwal, Director, bought 4,770 with an average share price of $52.40 per share and the total transaction amounting to $249,948.00.
- On 12/15/2017 Theodore R Samuels II, Director, bought 4,000 with an average share price of $62.30 per share and the total transaction amounting to $249,200.00.
- On 12/12/2017 Thomas J Jr. Lynch, EVP, sold 5,300 with an average share price of $63.24 per share and the total transaction amounting to $335,172.00.
- On 12/4/2017 Sandra Leung, EVP, sold 156,582 with an average share price of $63.37 per share and the total transaction amounting to $9,922,601.34.
- On 9/6/2017 Joseph C Caldarella, SVP, sold 9,340 with an average share price of $60.00 per share and the total transaction amounting to $560,400.00.
- On 8/2/2017 Theodore R Samuels II, Director, bought 6,000 with an average share price of $55.94 per share and the total transaction amounting to $335,640.00.
- On 4/7/2017 Lamberto Andreotti, Director, sold 34,000 with an average share price of $53.26 per share and the total transaction amounting to $1,810,840.00.
About Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; and Compugen Ltd.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Recent Trading Activity for Bristol-Myers Squibb Co (NYSE:BMY)
Shares of Bristol-Myers Squibb Co closed the previous trading session at 50,10 −2,62 4,98 % with 51.25 shares trading hands.